Matthew Buten compensation by year
Biohaven Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $551,250 | $573,300 | $596,232 |
| Bonus | $482,388 | $501,638 | $238,493 |
| Stock awards | — | — | $656,880 |
| Option awards | $1,701,221 | $2,945,471 | $3,001,762 |
| Non-equity incentive | — | — | $0 |
| Pension and deferred compensation | — | — | $0 |
| All other | $20,778 | $22,926 | $23,885 |
| Total | $2,755,637 | $4,043,335 | $4,517,252 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Biohaven Ltd. DEF 14A filed March 13, 2026, accession 0001935979-26-000028, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 12,750 | $143,948 | — |
| Option | 48,124 | — | $41.93 |
| Option | 78,000 | — | $38.64 |
| Option | 19,687 | — | $29.49 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Biohaven Ltd.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Biohaven discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control, no termination | $0 | $143,948 | $0 | $143,948 |
| Change in control and involuntary termination | $2,287,768 | $143,948 | $68,786 | $2,500,502 |
| Disability | $1,989,648 | $143,948 | $82,488 | $2,216,084 |
| Involuntary termination without cause | $1,989,648 | $143,948 | $82,488 | $2,216,084 |
| Death | $1,989,648 | $143,948 | $82,488 | $2,216,084 |
Per the Potential Payments Upon Termination or Change in Control table in Biohaven Ltd.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Biohaven’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Vlad Coric | Chief Executive Officer and Chairman of the Board of Directors | $13,500,438 |
| Bruce Car | Chief Scientific Officer | $4,768,188 |
| Matthew Buten · this page | Chief Financial Officer | $4,517,252 |
| Kimberly Gentile | Senior Vice President, Clinical Operations | $3,963,864 |
The full Biohaven compensation record
free company briefThis page is one person within Biohaven's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Biohaven's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Biohaven's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat